Bavituximab Current Events | Bavituximab News
|
|
|
Sort By:
Page Views | Date |
Arsenic aids tumor imaging when joined to cancer-homing drug, UT Southwestern researchers find
Arsenic linked to a drug that binds to the blood vessels of cancerous tumors provides a powerful imaging agent that could one day allow physicians to detect hard-to-find tumors and more closely monitor cancer's response to therapy, researchers at UT Southwestern Medical Center have found. view more (2008-03-03)
UT Southwestern researchers develop new strategy for broad spectrum anti-viral drugs
Bavituximab, an anti-viral drug developed by UT Southwestern Medical Center researchers, shows promise as a new strategy to fight viral diseases, including potential bioterrorism agents. view more (2008-11-24)
Nature Medicine study shows Peregrine's bavituximab can cure lethal virus infections
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today reported publication of data in Nature Medicine that supports the broad anti-viral potential of the company's novel anti-phosphatidylserine (anti-PS) antibody platform, showing that its PS-targeting drug bavituximab can cure lethal virus infections in animal disease models. view more (2008-11-24)
Peregrine's PS-targeting antibodies highlighted in AACR Annual Meeting studies
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and serious virus infections, today reported that two preclinical studies presented during the AACR 100th Annual Meeting 2009 provided further confirmation of the immunomodulatory mechanisms... view more... (2009-04-22)
|
|
|
|
Sort By:
Page Views | Date |
|
